OverviewSuggest Edit

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. The Company's pipeline is comprised of cell-based therapies for cancer and immune disorders. Its cellular immunotherapies are based on ex vivo cell programming approach to modulate the therapeutic function and direct the fate of hematopoietic cells.

TypePublic
Founded2007
HQSan Diego, CA, US
Websitefatetherapeutics.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2019)178(+72%)
Job Openings72
Revenue (FY, 2020)$31.4 M(+195%)
Share Price (Oct 2021)$62.5(+4%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Fate Therapeutics

Scott Wolchko

Scott Wolchko

President & CEO, Director
William Rastetter

William Rastetter

Chairman
Dan Shoemaker

Dan Shoemaker

Chief Scientific Officer
John Mendlein

John Mendlein

Vice Chairman
Edward Dulac

Edward Dulac

Chief Financial Officer
Bob Valamehr

Bob Valamehr

Chief Development Officer
Show more

Fate Therapeutics Office Locations

Fate Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
3535 General Atomics Ct
San Diego, CA, US
12278 Scripps Summit Dr
Show all (2)

Fate Therapeutics Financials and Metrics

Fate Therapeutics Revenue

Fate Therapeutics's revenue was reported to be $31.43 m in FY, 2020
USD

Revenue (Q1, 2021)

11.1m

Net income (Q1, 2021)

(45.1m)

EBIT (Q1, 2021)

(46.2m)

Market capitalization (14-Oct-2021)

5.9b

Closing stock price (14-Oct-2021)

62.5

Cash (31-Mar-2021)

106.4m

EV

5.9b
Fate Therapeutics's current market capitalization is $5.9 b.
Annual
USDFY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

971.0k971.0k2.4m2.4m4.4m4.1m4.7m10.7m31.4m

Revenue growth, %

(81%)150%

General and administrative expense

6.6m8.5m10.4m9.9m11.9m15.8m23.6m33.9m

R&D expense

12.0m16.4m19.9m26.5m34.4m56.0m87.8m125.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

209.0k329.0k1.0m1.3m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m2.6m2.8m2.4m2.5m5.5m7.6m11.1m

General and administrative expense

2.0m2.4m2.1m1.9m2.8m2.7m2.4m2.6m2.2m2.6m3.0m2.7m2.8m3.6m3.8m4.1m5.4m5.3m6.3m7.7m7.5m8.4m12.5m

R&D expense

3.4m4.5m4.0m4.1m4.6m4.9m5.0m6.6m6.8m6.8m8.0m7.9m8.6m11.5m16.8m13.6m17.7m21.6m23.2m29.3m26.7m30.7m44.9m

Operating expense total

5.4m6.9m6.0m6.0m7.3m7.5m7.4m9.2m9.0m9.4m11.0m10.6m11.4m15.1m20.6m17.7m23.1m26.9m29.5m37.0m34.2m39.0m57.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

54.0m49.1m64.8m88.6m89.0m190.5m99.8m167.3m

Accounts Receivable

500.0k5.5m

Prepaid Expenses

615.0k771.0k843.0k1.6m3.7m5.7m5.9m

Inventories

1.2m
USDQ3, 2013

Financial Leverage

-0.3 x
Show all financial metrics

Fate Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Fate Therapeutics Online and Social Media Presence

Embed Graph

Fate Therapeutics News and Updates

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company’…

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells

Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an indepen…

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 cli…

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Office…
Show more

Fate Therapeutics Blogs

599CC, Senior Scientist, Cancer Immunotherapy (T cell enhancement)

Job Code 599CC Description Fate Therapeutics is in search of a talented and motivated individual to become part of our T cell cancer immunotherapy team. Our rapidly growing team is part of a great effort to develop allogeneic, off-the-shelf adoptive cell therapy products. The successful candidate wi…

598MHE, Commercial Contracts Counsel

Job Code 598MHE Description Fate Therapeutics’ legal group is seeking a career oriented attorney with significant life sciences experience to provide transactional support for the Company’s operations, with a particular focus on implementing agreements to support operations and product development. …

597CK, Quality Assurance Associate I

Job Code 597CK Description Fate Therapeutics is seeking a motivated and talented Quality Assurance Associate to assure adherence to standard operating procedures, GxP guidelines, and applicable regulations. The ideal candidate must thrive in a fast-paced team environment and must have excellent atte…

596CK, Quality Assurance Associate III / II, Analytical Quality

Job Code 596CK Description Fate Therapeutics is seeking a motivated and talented individual to assure adherence to standard operating procedures, GxP guidelines, and applicable regulations. The ideal candidate must thrive in a fast-paced team environment and must have excellent attention to detail, …

595GDB, Senior Buyer, Supply Chain

Job Code 595GDB Description Fate Therapeutics is currently seeking a motivated buyer to support raw material management at Fate’s manufacturing and R&D facilities. The successful candidate will ensure material availability to support Fate’s clinical, commercial, and R&D Operations, for all p…

594VH, Associate Director / Senior Manager, R&D Finance

Job Code 594VH Description Fate Therapeutics is currently seeking a Associate Director or Senior Manager of R&D Finance. This role will support initiatives included in budgeting, tracking, forecasting, and strategic planning across our rapidly growing and progressing clinical stage portfolio. Th…
Show more

Fate Therapeutics Frequently Asked Questions

  • When was Fate Therapeutics founded?

    Fate Therapeutics was founded in 2007.

  • Who are Fate Therapeutics key executives?

    Fate Therapeutics's key executives are Scott Wolchko, William Rastetter and Dan Shoemaker.

  • How many employees does Fate Therapeutics have?

    Fate Therapeutics has 178 employees.

  • What is Fate Therapeutics revenue?

    Latest Fate Therapeutics annual revenue is $31.4 m.

  • What is Fate Therapeutics revenue per employee?

    Latest Fate Therapeutics revenue per employee is $176.6 k.

  • Who are Fate Therapeutics competitors?

    Competitors of Fate Therapeutics include AlloVir, Genewiz and Nexelis.

  • Where is Fate Therapeutics headquarters?

    Fate Therapeutics headquarters is located at 3535 General Atomics Ct, San Diego.

  • Where are Fate Therapeutics offices?

    Fate Therapeutics has an office in San Diego.

  • How many offices does Fate Therapeutics have?

    Fate Therapeutics has 2 offices.